Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-Year results

M. S. Soloway, K. Pareek, R. Sharifi, Z. Wajsman, D. McLeod, Jr Wood D.P., A. Puras-Baez, M. S. Austenfeld, M. K. Brawer, R. Bruskewitz, G. Chodak, S. K. Coffield, C. F. Johnson, O. E. Teague, S. Peretsman, I. Thompson, W. Cooner, H. A G Fisher, A. Melman, N. StoneE. Klein, B. Malkowicz, R. Middleton, P. Nieh, J. O. Peabody, J. M. Pow-Sang, S. Rous, J. Schmidt, A. Smith

Research output: Contribution to journalArticle

268 Citations (Scopus)

Abstract

Purpose: In the initial report of the Lupron Depot Neoadjuvant Prostate Cancer Study Group patients who received 3 months of androgen deprivation had a significant decrease in the positive margin rate. We monitored these patients for 5 years and to our knowledge present the longest followup of any neoadjuvant trial. Materials and Methods: A multi-institutional prospective randomized trial was performed between February 1992 and April 1994 involving patients with stage cT2b prostate cancer, including 138 who received 3 months of leuprolide plus flutamide before radical prostatectomy and 144 who underwent radical prostatectomy only. Patients were followed every 6 months with serum prostate specific antigen (PSA) testing for 5 years. Biochemical recurrence was defined as PSA greater than 0.4 ng./ml. Results: At 5 years there was no difference in the biochemical recurrence rate. PSA was less than 0.4 ng./ml. in 64.8% of the patients in the neoadjuvant androgen ablation plus prostatectomy and 67.6% in the prostatectomy only group (p = 0.663). Conclusions: Although 3 months of androgen deprivation before radical prostatectomy resulted in an apparently significant decrease in positive surgical margins, a 5-year followup does not indicate any difference in the recurrence rate. Until studies document improvement in biochemical or clinical recurrence with longer periods of treatment, induction androgen deprivation before radical prostatectomy is not indicated.

Original languageEnglish (US)
Pages (from-to)112-116
Number of pages5
JournalJournal of Urology
Volume167
Issue number1
StatePublished - 2002
Externally publishedYes

Fingerprint

Prostatectomy
Androgens
Prostatic Neoplasms
Prostate-Specific Antigen
Leuprolide
Recurrence
Flutamide
Serum

Keywords

  • Leuprolide
  • Neoadjuvant therapy
  • Prostate
  • Prostatectomy
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Soloway, M. S., Pareek, K., Sharifi, R., Wajsman, Z., McLeod, D., Wood D.P., J., ... Smith, A. (2002). Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-Year results. Journal of Urology, 167(1), 112-116.

Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer : 5-Year results. / Soloway, M. S.; Pareek, K.; Sharifi, R.; Wajsman, Z.; McLeod, D.; Wood D.P., Jr; Puras-Baez, A.; Austenfeld, M. S.; Brawer, M. K.; Bruskewitz, R.; Chodak, G.; Coffield, S. K.; Johnson, C. F.; Teague, O. E.; Peretsman, S.; Thompson, I.; Cooner, W.; Fisher, H. A G; Melman, A.; Stone, N.; Klein, E.; Malkowicz, B.; Middleton, R.; Nieh, P.; Peabody, J. O.; Pow-Sang, J. M.; Rous, S.; Schmidt, J.; Smith, A.

In: Journal of Urology, Vol. 167, No. 1, 2002, p. 112-116.

Research output: Contribution to journalArticle

Soloway, MS, Pareek, K, Sharifi, R, Wajsman, Z, McLeod, D, Wood D.P., J, Puras-Baez, A, Austenfeld, MS, Brawer, MK, Bruskewitz, R, Chodak, G, Coffield, SK, Johnson, CF, Teague, OE, Peretsman, S, Thompson, I, Cooner, W, Fisher, HAG, Melman, A, Stone, N, Klein, E, Malkowicz, B, Middleton, R, Nieh, P, Peabody, JO, Pow-Sang, JM, Rous, S, Schmidt, J & Smith, A 2002, 'Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-Year results', Journal of Urology, vol. 167, no. 1, pp. 112-116.
Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood D.P. J et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-Year results. Journal of Urology. 2002;167(1):112-116.
Soloway, M. S. ; Pareek, K. ; Sharifi, R. ; Wajsman, Z. ; McLeod, D. ; Wood D.P., Jr ; Puras-Baez, A. ; Austenfeld, M. S. ; Brawer, M. K. ; Bruskewitz, R. ; Chodak, G. ; Coffield, S. K. ; Johnson, C. F. ; Teague, O. E. ; Peretsman, S. ; Thompson, I. ; Cooner, W. ; Fisher, H. A G ; Melman, A. ; Stone, N. ; Klein, E. ; Malkowicz, B. ; Middleton, R. ; Nieh, P. ; Peabody, J. O. ; Pow-Sang, J. M. ; Rous, S. ; Schmidt, J. ; Smith, A. / Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer : 5-Year results. In: Journal of Urology. 2002 ; Vol. 167, No. 1. pp. 112-116.
@article{26fd5e849cbd416d8a3560753ecf22cb,
title = "Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-Year results",
abstract = "Purpose: In the initial report of the Lupron Depot Neoadjuvant Prostate Cancer Study Group patients who received 3 months of androgen deprivation had a significant decrease in the positive margin rate. We monitored these patients for 5 years and to our knowledge present the longest followup of any neoadjuvant trial. Materials and Methods: A multi-institutional prospective randomized trial was performed between February 1992 and April 1994 involving patients with stage cT2b prostate cancer, including 138 who received 3 months of leuprolide plus flutamide before radical prostatectomy and 144 who underwent radical prostatectomy only. Patients were followed every 6 months with serum prostate specific antigen (PSA) testing for 5 years. Biochemical recurrence was defined as PSA greater than 0.4 ng./ml. Results: At 5 years there was no difference in the biochemical recurrence rate. PSA was less than 0.4 ng./ml. in 64.8{\%} of the patients in the neoadjuvant androgen ablation plus prostatectomy and 67.6{\%} in the prostatectomy only group (p = 0.663). Conclusions: Although 3 months of androgen deprivation before radical prostatectomy resulted in an apparently significant decrease in positive surgical margins, a 5-year followup does not indicate any difference in the recurrence rate. Until studies document improvement in biochemical or clinical recurrence with longer periods of treatment, induction androgen deprivation before radical prostatectomy is not indicated.",
keywords = "Leuprolide, Neoadjuvant therapy, Prostate, Prostatectomy, Prostatic neoplasms",
author = "Soloway, {M. S.} and K. Pareek and R. Sharifi and Z. Wajsman and D. McLeod and {Wood D.P.}, Jr and A. Puras-Baez and Austenfeld, {M. S.} and Brawer, {M. K.} and R. Bruskewitz and G. Chodak and Coffield, {S. K.} and Johnson, {C. F.} and Teague, {O. E.} and S. Peretsman and I. Thompson and W. Cooner and Fisher, {H. A G} and A. Melman and N. Stone and E. Klein and B. Malkowicz and R. Middleton and P. Nieh and Peabody, {J. O.} and Pow-Sang, {J. M.} and S. Rous and J. Schmidt and A. Smith",
year = "2002",
language = "English (US)",
volume = "167",
pages = "112--116",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer

T2 - 5-Year results

AU - Soloway, M. S.

AU - Pareek, K.

AU - Sharifi, R.

AU - Wajsman, Z.

AU - McLeod, D.

AU - Wood D.P., Jr

AU - Puras-Baez, A.

AU - Austenfeld, M. S.

AU - Brawer, M. K.

AU - Bruskewitz, R.

AU - Chodak, G.

AU - Coffield, S. K.

AU - Johnson, C. F.

AU - Teague, O. E.

AU - Peretsman, S.

AU - Thompson, I.

AU - Cooner, W.

AU - Fisher, H. A G

AU - Melman, A.

AU - Stone, N.

AU - Klein, E.

AU - Malkowicz, B.

AU - Middleton, R.

AU - Nieh, P.

AU - Peabody, J. O.

AU - Pow-Sang, J. M.

AU - Rous, S.

AU - Schmidt, J.

AU - Smith, A.

PY - 2002

Y1 - 2002

N2 - Purpose: In the initial report of the Lupron Depot Neoadjuvant Prostate Cancer Study Group patients who received 3 months of androgen deprivation had a significant decrease in the positive margin rate. We monitored these patients for 5 years and to our knowledge present the longest followup of any neoadjuvant trial. Materials and Methods: A multi-institutional prospective randomized trial was performed between February 1992 and April 1994 involving patients with stage cT2b prostate cancer, including 138 who received 3 months of leuprolide plus flutamide before radical prostatectomy and 144 who underwent radical prostatectomy only. Patients were followed every 6 months with serum prostate specific antigen (PSA) testing for 5 years. Biochemical recurrence was defined as PSA greater than 0.4 ng./ml. Results: At 5 years there was no difference in the biochemical recurrence rate. PSA was less than 0.4 ng./ml. in 64.8% of the patients in the neoadjuvant androgen ablation plus prostatectomy and 67.6% in the prostatectomy only group (p = 0.663). Conclusions: Although 3 months of androgen deprivation before radical prostatectomy resulted in an apparently significant decrease in positive surgical margins, a 5-year followup does not indicate any difference in the recurrence rate. Until studies document improvement in biochemical or clinical recurrence with longer periods of treatment, induction androgen deprivation before radical prostatectomy is not indicated.

AB - Purpose: In the initial report of the Lupron Depot Neoadjuvant Prostate Cancer Study Group patients who received 3 months of androgen deprivation had a significant decrease in the positive margin rate. We monitored these patients for 5 years and to our knowledge present the longest followup of any neoadjuvant trial. Materials and Methods: A multi-institutional prospective randomized trial was performed between February 1992 and April 1994 involving patients with stage cT2b prostate cancer, including 138 who received 3 months of leuprolide plus flutamide before radical prostatectomy and 144 who underwent radical prostatectomy only. Patients were followed every 6 months with serum prostate specific antigen (PSA) testing for 5 years. Biochemical recurrence was defined as PSA greater than 0.4 ng./ml. Results: At 5 years there was no difference in the biochemical recurrence rate. PSA was less than 0.4 ng./ml. in 64.8% of the patients in the neoadjuvant androgen ablation plus prostatectomy and 67.6% in the prostatectomy only group (p = 0.663). Conclusions: Although 3 months of androgen deprivation before radical prostatectomy resulted in an apparently significant decrease in positive surgical margins, a 5-year followup does not indicate any difference in the recurrence rate. Until studies document improvement in biochemical or clinical recurrence with longer periods of treatment, induction androgen deprivation before radical prostatectomy is not indicated.

KW - Leuprolide

KW - Neoadjuvant therapy

KW - Prostate

KW - Prostatectomy

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0036135882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036135882&partnerID=8YFLogxK

M3 - Article

C2 - 11743286

AN - SCOPUS:0036135882

VL - 167

SP - 112

EP - 116

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -